top of page

Proteomics international Laboratories Ltd (PIQ.ASX). 

Biotechnology: Diagnostics

About PIQ

Proteomics International Laboratories Ltd (PIQ.ASX) is a revenue generating medical technology company at the forefront of precision medicine and predictive diagnostics. In conjunction with Sonic Healthcare USA, PIQ is currently rolling out its world-first, predictive diagnostic test, PromarkerD, which can predict the onset of diabetic kidney disease (DKD) before clinical symptoms appear, up to four years in advance.

​

Proteomics International has several diagnostics in its pipeline, namely a world first blood test for Endometriosis (affects 1 in 9 women), and Oesophageal Cancer (1 in 20 cancer deaths). These diagnostics are in the final stages of validation and if successful present blockbuster opportunties.

Candour and PIQ

In a previous role Dirk and Alastair assisted PIQ’s IPO. We subsequently followed the Company closely and were formally engaged in 2018.

​

We have played a critical role in the transformation of PIQ, focusing the company’s messaging, successfully executing three capital raises, at successively higher prices, introducing supportive brokers & institutions (national & international) to the register.

 

These initiatives have resulted in a supportive shareholder base that has re-rated the company 4-6x. We continue to provide advice, preparing the company for key commercialisation milestones.  

Candour Commentary 

Recent Announcement Example

1 / Item Title

1 / Item Title

2 / Item Title
3 / Item Title

Successful Capital Raises

Candour Advisory

Candour Advisory Pty Ltd ABN 64 628 454 839 is a Corporate Authorised Representative No. 001305071 of SA Capital Pty Ltd ABN 78 114 959 803 AFSL No. 291787

Address

Suite 101, 147 Pirie Street

Adelaide 

SA 5000

bottom of page